Navigation Links
Bionovo Announces Publication Describing First Novel Dual mTOR Inhibitor, BN107, for the Treatment of Breast Cancer
Date:12/29/2009

or the anti-tumor effect of BN107. Simply put, BN107 has a unique way to target a specific sub-group of breast cancer cells that currently has no selective treatment. This is exciting."

"It is critical to develop novel and safe strategies to effectively treat the patients with ER- breast cancers. We believe BN107 will result in better selectivity to hormone independent tumors based on its unique selectivity and mechanisms of action. Currently the only available treatment for this group, constituting 40% of women diagnosed with breast cancer, is chemotherapy. BN107, an oral drug candidate, should provide a chronic treatment option with a low toxicity profile," said Dr. Isaac Cohen, Chairman and CEO of Bionovo.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Bionovo to Present on Novel Female-Specific Drugs for Obesity at the 20th Annual Meeting of the North American Menopause Society
2. Bionovo, Inc. to Announce Second Quarter Fiscal Year 2009 Financial Results on Monday, August 10, 2009
3. Bionovo Appoints Dr. Klaus Kohl as Chief Technical Officer
4. Bionovo Announces Publication of Data on Active Compound and Mechanism of Action for Its Preclinical Cancer Treatment, BN108
5. Bionovo Announces 2008 Highlights and Year-End Financial Results
6. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
7. Bert W. OMalley, M.D., Recipient of the 2008 National Medal for Science, Joins Bionovos Scientific Advisory Board
8. Bionovo Publishes Discoveries in Predictable Tissue Selectivity for Selective Estrogen Receptor Modulators Platform
9. Bionovo to Present Recent Findings of BN107, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium
10. Bionovo to Present at the Piper Jaffray Healthcare Conference
11. Ethan Weiss, M.D., Joins Bionovos Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... California (PRWEB) September 17, 2014 ... naturally occurring microorganisms such as bacteria, fungi, and ... into water, methane, biomass, inorganic compounds, carbon dioxide, ... processability, expanding customer base and improved costs, biodegradable ... and economically viable alternative to conventional polymers. Primary ...
(Date:9/17/2014)... 2014 Immunomic Therapeutics, Inc. announced today ... grant to support the continued preclinical development of a ... approximately $255,000 over one year to conduct vaccine validation ... allergy, affect over one million Americans and are the ... nut exposure is also a risk for peanut allergics, ...
(Date:9/17/2014)... -- Hussey Copper , a leader in copper ... announces Gilmour Academy Ice Arena,s conversion of more than ... touch surface to help protect against bacteria.  MD-Cu 29 ... kills greater than 99.9% of MRSA, E-coli and other ... , Innovative Gilmour Academy prepares ...
(Date:9/17/2014)... SAN FRANCISCO, Calif. , Sept. 17, 2014 /PRNewswire/ ... ), a molecular diagnostics company pioneering the field of ... Hall to chief operating officer. Mr. Hall ... spearhead the company,s commercial entry into endocrinology. Since 2012, ... operations, as well as managed care and billing functions. ...
Breaking Biology Technology:Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4
(Date:9/17/2014)... a great deal about complex social behavior by studying ... to teach too. , With their unusually large brains ... live in a complex social environment---not merely in a ... ants, but in a dynamic setting of alliances and ... mammals: dolphins, whales, primates, and social carnivores, like hyenas ...
(Date:9/16/2014)... American Menopause Society (NAMS) has published its key, ... womenon everything from hot flashes to heart disease. ... Recommendations for Clinical Care of Midlife Women," was ... Menopause . This is the first, comprehensive set ... women freely available to all clinicians who care ...
(Date:9/16/2014)... that we inherit certain traits from our parents that ... these genes play out by taking certain drugs or ... what a team of researchers at the Boston University ... of epigenetics research. , Epigenetics regulates gene expression ... histone proteins, which prevent permanent mutations or alterations within ...
Breaking Biology News(10 mins):Being social: Learning from the behavior of birds 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3
... 29, 2010) -- Wind turbines may be one of ... larger they also get noisier, become more of an ... solution: ocean-based wind turbines. While offshore turbines already have ... where the tower extends directly into the seabed. That ...
... -- The U.S. Supreme Court ruled 5-4 Monday that a ... the ability to patent software should not be limited. ... the "machine or transformation" test is not the sole test ... however, cannot be patented. IEEE-USA was party to an ...
... the Arctic climate system may be more sensitive to greenhouse ... atmospheric carbon dioxide may be high enough to bring about ... University of Colorado at Boulder, the international study indicated that ... High Arctic during the Pliocene Epoch 2.6 to 5.3 million ...
Cached Biology News:Arctic climate may be more sensitive to warming than thought, says new study 2Arctic climate may be more sensitive to warming than thought, says new study 3Arctic climate may be more sensitive to warming than thought, says new study 4
Complement C1q subcomponent subunit C precursor. [Source:Uniprot/SWISSPROT;Acc:P02747] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Monoclonal Mouse Anti-Human Cytokeratin 16 (48 kD)...
Mouse monoclonal [CRC64] to Integrin alpha 2b + beta 3 ( Abpromise for all tested applications). Antigen: Human platelets Entrez Gene ID: 23295 Swiss Protein ID: P05106...
PFM8 Antibody...
Biology Products: